Christine M. Palermo, Ph.D., DABT

Director of Regulatory Sciences

F: 202-557-3836

Overview

Christine M. Palermo, Ph.D., DABT, is Director of Regulatory Sciences at The Acta Group (Acta®). Dr. Palermo provides Acta clients with global strategy in chemical regulatory compliance, risk assessment, and product stewardship, assisting clients to commercialize new products and expand markets for existing product portfolios. Dr. Palermo deploys the extensive U.S. domestic and international experience she gained as a regulatory sciences principal and leader of global toxicology for ExxonMobil (EM) Biomedical Sciences to advise Acta clients regarding ongoing and anticipated regulatory risk management in the United States, European Union (EU), and Asia for new and existing chemicals and chemical products, including those subject to heavy regulatory scrutiny.

Dr. Palermo is a recognized leader in the advancement of science-based regulatory decision-making. Through her involvement with the European Chemical Industry Council (CEFIC), the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), the World Health Organization/International Programme on Chemical Safety Mode of Action/Human Relevance Framework (WHO/IPCS MOA HRF), and other industry organizations, Dr. Palermo has worked to evolve the internationally recognized evidence integration framework for assessing human relevance of chemical mediated outcomes in animals, and to advance technical approaches for endocrine disruptor identification, reproductive hazard identification, and a risk-based polymer safety decision framework to inform chemical management approaches. She has a long and distinguished bibliography of peer-reviewed scientific papers and articles published in Reproductive Toxicology, Toxicology Letters, and Regulatory Toxicology and Pharmacology, among other prominent scientific journals.

Professional and Community Involvement

Diplomate, American Board of Toxicology (ABT) 2010 –
Member of the Society of Toxicology (SOT) 2001 –

Articles and Writings

Lea IA, Buerger AN, Feifarek D, Mihalchik A, Heintz MM, Haws LC, Nyambego H, Goyak K, Palermo C, Borghoff SJ. 2024. Evaluation of the endocrine disrupting potential of di-isononyl phthalate.
Lea IA, Feifarek D, Mihalchik A, Heintz M, Haws L, Nyambego H, Goyak K, Palermo C, Borghoff SJ. 2024. Evaluation of the endocrine disrupting potential of di-isodecyl phthalate.
Rogers JM, Buerger AN, Palermo C, Heintz MM, Haws LC, Lea IA. 2024. Evaluation of a Sertoli cell based adverse outcome pathway for effects of DINP on the developing male reproductive tract.
Palermo CM, Foreman JE, Wikoff DS, Lea I. 2021. Development of a putative adverse outcome pathway network for male rat reproductive tract abnormalities with specific considerations for the androgen sensitive window of development. Curr Res Toxicol. 2:254-271. doi: 10.1016/j.crtox.2021.07.002.

van den Driesche S, Shocker S, Palermo C, Inglis F, Langsh A, Otter R. 2020. Systematic comparison of the male reproductive tract in fetal and adult Wistar rats exposed to DBP and DINP in utero during the masculinisation programming window. Toxicology letters 335:37-50. https://doi.org/10.1016/j.toxlet.2020.10.006.
Morfeld P, Chen M, Otter R, Palermo C, Kemmerling J, Mastrantonio M. 2017. Boberg et al. (2011) — Corrigendum (2016): Further significant modifications needed. Reproductive Toxicology. 71:159-161. doi.org/10.1016/j.reprotox.2017.03.013.
Chen M, Alyea R, Morfeld P, Otter, R, Kemmerling J, Palermo C. 2017. Reproducibility discrepancies following reanalysis of raw data for a previously published study on diisononyl phthalate (DINP) in rats. Data in Brief. 13:208-213. doi.org/10.1016/j.dib.2017.05.043.
Becker RA, Dellarco V, Seed J, Kronenberg JM, Meek B, Foreman J, Palermo C, Kirman C, Linkov I, Schoeny R, Dourson M, Pottenger LH, Manibusan MK. 2017. Quantitative weight of evidence to assess confidence in potential modes of action. Reg. Tox. Pharm. 86:205-220. https://doi.org/10.1016/j.yrtph.2017.02.017.
Moore NP, Beekhuijzen M, Boogaard PJ, Foreman JE, North CM, Palermo C, Schneider S, Strauss V, van Ravenzwaay B, Poole, A. 2016. Guidance on the selection of cohorts for the extended one-generation reproduction toxicity study (OECD test guideline 443). Reg. Tox. Pharm. 80:32-40. https://doi.org/10.1016/j.yrtph.2016.05.036.
Bette Meek ME, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. 2014. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. Appl Toxicol. 34(6):595-606. doi: 10.1002/jat.2984.
Greim H, Kaden DA, Larson RA, Palermo CM, Rice JM, Ross D, Snyder R. 2014. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 1310(1):7-31. doi: 10.1111/nyas.12362.
Ahsan SA, Lackovic M, Katner A, Palermo C. 2009. Metal fume fever: a review of the literature and cases reported to the Louisiana Poison Control Center. The J. La State Med Soc. 161:348-51.
Palermo CM, Bennett CA, Winters AC, Hemenway CS. 2008. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leuk Res. 32(4):633-42. doi: 10.1016/j.leukres.2007.08.002.
Palermo CM, Westlake CA, Gasiewicz TA. 2005. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry. 44(13):5041-52. doi: 10.1021/bi047433p.
Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA. Reiners JJ. 2003. The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab. Dispos. 31(11):1279-82. doi: 10.1124/dmd.31.11.1279.
Zhou JG, Henry EC, Palermo CM, Dertinger SD, Gasiewicz TA. 2003. Species-specific transcriptional activity of synthetic flavonoids in guinea pig and mouse cells as a result of differential activation of the aryl hydrocarbon receptor to interact with dioxin-responsive elements. Mol Pharmacol. 63(4):915-24. doi: 10.1124/mol.63.4.915.
Palermo CM, Martin Hernando JI, Dertinger SD, Kende AS, Gasiewicz TA. 2003. Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol. 16(7):865-72. doi: 10.1021/tx025672c.

B&C, Acta, and BCCM provide a full range of global support for the commercialisation of chemicals, biocides, and products of industrial biotechnology, nanotechnology, and synthetic biology.

View Our Services

Christine M. Palermo, Ph.D., DABT

Overview

Professional and Community Involvement

Articles and Writings

B&C, Acta, and BCCM provide a full range of global support for the commercialisation of chemicals, biocides, and products of industrial biotechnology, nanotechnology, and synthetic biology.

Education

Our Firms

Our Practice Areas

Seminars and Webinars

Resources

Tools and Training

Podcasts